Intech Investment Management LLC lifted its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 13.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,037 shares of the company’s stock after purchasing an additional 16,212 shares during the period. Intech Investment Management LLC’s holdings in AstraZeneca were worth $21,866,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in AZN. Roxbury Financial LLC acquired a new stake in AstraZeneca during the 2nd quarter valued at $29,000. Resources Management Corp CT ADV acquired a new position in AstraZeneca in the 1st quarter worth $35,000. Allied Private Wealth LLC acquired a new position in AstraZeneca in the 2nd quarter worth $35,000. Laurel Wealth Advisors LLC acquired a new position in AstraZeneca in the 3rd quarter worth $30,000. Finally, GK Wealth Management LLC purchased a new position in AstraZeneca in the 3rd quarter valued at about $31,000. 20.35% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on AZN shares. Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Deutsche Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, CICC Research started coverage on AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.
View Our Latest Stock Report on AZN
AstraZeneca Stock Performance
Shares of AstraZeneca stock opened at $184.66 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.79 and a current ratio of 1.01. AstraZeneca Plc has a 1 year low of $153.41 and a 1 year high of $212.71. The firm’s 50-day simple moving average is $168.82 and its 200-day simple moving average is $180.20. The firm has a market cap of $286.40 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24.
AstraZeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. The business had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The company’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period last year, the firm earned $2.38 earnings per share. Equities analysts forecast that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.
AstraZeneca Company Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Further Reading
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
